Healthcare / BiotechnologyTaipei Exchange
$13.55
+0.15 (+1.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-9.8M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$593M
P/E
6.2x
↓EV/EBITDA
5.4x
↓ROE
19.8%
↑Gross Margin
35.3%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.7%
FCF CAGR
—
FCF margin
-15.9%
FCF / Net income
-0.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $61.4M · net income $96.2M · FCF $-9.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.4M | $61.4M | $57.8M | $55.9M | $42.9M |
| Net Income | $96.2M | $96.2M | $-40.1M | $-6.6M | $-26.4M |
| EBITDA | $104.3M | $104.3M | $-31.3M | $-7.0M | $-21.7M |
| EPS | — | — | -0.92 | -0.15 | -0.60 |
| Gross Margin | 35.3% | 35.3% | 29.4% | 29.4% | 1.6% |
| Operating Margin | -35.7% | -35.7% | -45.0% | -28.9% | -71.2% |
| Net Margin | 156.6% | 156.6% | -69.3% | -11.8% | -61.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | — | — | — |
| Current Ratio | 11.85 | 11.85 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.8M | $-9.8M | $-14.4M | $-3.5M | $13.8M |
| Returns | |||||
| ROE | 19.8% | 19.8% | -10.3% | -1.5% | -6.0% |
| Valuation | |||||
| P/E | 6.19 | 6.19 | — | — | — |
| EV/EBITDA | 5.44 | 5.44 | — | — | — |
| P/B | 1.22 | 1.22 | 1.63 | 1.99 | 1.15 |
| Growth & Yield | |||||
| Revenue Growth | 6.3% | 6.3% | 3.4% | 30.2% | — |
| EPS Growth | — | — | -513.3% | 75.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.92 → n/d
Residual
+4.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.